SLC6A3 and Parkinson disease: Using the experimental PD models of MPTP-treated σ1R+/− mice and σ1R−/− mice, the present study provides in vivo evidence that the σ1R deficiency through suppressing NMDAr function and DAT expression can attenuate MPTP-induced dopaminergic neurodegeneration and parkinsonism.